Vycor Medical Inc. · OTC:VYCO

Vycor Medical — Investor Presentation (April 2025)

32 slides from Vycor Medical's investor presentation, April 2025

  1. Slide 1: Corporate Presentation 2025

    Slide 1: Corporate Presentation 2025

    OTCQB:VYCO Corporate Presentation 2025

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    OTCQB:VYCO Safe Harbor Statement Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimat

  3. Slide 3: Who We Are

    Slide 3: Who We Are

    OTCQB:VYCO Who We Are  Vycor Medical is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions.  We have a portfolio of FDA cleared medical solutions that are changing and improving lives every day.  Our main product lines are: ViewSiteTM and

  4. Slide 4: Our Two Product Lines

    Slide 4: Our Two Product Lines

    OTCQB:VYCO Our Two Product Lines ViewSite NovaVision has a family of complementary therapies that diagnose Lead product ViewSite Brain Access System (VBAS) is a (VIDIT) and both restore (Visual Restoration Therapy® “VRT”) and revolutionary neurosurgical device used to retract and gain compensate (Ne

  5. Slide 5: Vycor Medical's Strategic Vision

    Slide 5: Vycor Medical's Strategic Vision

    OTCQB:VYCO Vycor Medical’s Strategic Vision Vycor Medical’s Strategic Vision 5

  6. Slide 6: Vycor Medical's Strategic Vision - Overview

    Slide 6: Vycor Medical's Strategic Vision - Overview

    OTCQB:VYCO Vycor Medical’s Strategic Vision - Overview Vycor’s near term corporate strategic objective is to gain the critical mass and growth profile required to uplist to a recognized exchange through acquisitions and mergers Vycor is well placed as a platform to deliver this objective:  OTCQB li

  7. Slide 7: Vycor Medical's Strategic Vision – Vycor

    Slide 7: Vycor Medical's Strategic Vision – Vycor

    OTCQB:VYCO Vycor Medical’s Strategic Vision – Vycor Vycor’s VBAS is a high margin niche medical device viewed as a “must have” by neurosurgeons for certain procedures. This gives Vycor tremendous reach and strength in distribution of existing and new products and a quality cachet for products neuros

  8. Slide 8: Vycor Medical's Strategic Vision – NovaVision

    Slide 8: Vycor Medical's Strategic Vision – NovaVision

    OTCQB:VYCO Vycor Medical’s Strategic Vision – NovaVision NovaVision is revenue generating with validated products that provide an unmet need with an opportunity for growth and is well-positioned in the fast- growing global trend towards digital health and telehealth – however requires significant th

  9. Slide 9: Vycor Medical Product Lines: ViewSite Brain Access System (VBAS)

    Slide 9: Vycor Medical Product Lines: ViewSite Brain Access System (VBAS)

    OTCQB:VYCO Vycor Medical Product Lines ViewSiteTM Brain Access System (VBAS) 9

  10. Slide 10: ViewSite Brain Access System (VBAS)

    Slide 10: ViewSite Brain Access System (VBAS)

    OTCQB:VYCO ViewSiteTM Brain Access System (VBAS) “It is the ideal system for providing deep brain access through a smaller incision.” -Neurosurgeon Quote 10

  11. Slide 11: ViewSite: The Future Standard of Care

    Slide 11: ViewSite: The Future Standard of Care

    OTCQB:VYCO ViewSiteTM : The Future Standard of Care • Less brain tissue damage Old Blade/Ribbon Retractor Technology • Less invasive: requires smaller opening • Better access • Better visibility • Self-contained working channel • Reduced operating and recovery time VS. VBAS Next Generation Technolog

  12. Slide 12: Market and Clinical Need for VBAS

    Slide 12: Market and Clinical Need for VBAS

    OTCQB:VYCO Market and Clinical Need for VBAS  Since the introduction of the first operative microscope 50+ years ago, microsurgery (and more recently endoscopic surgery) has become an indispensable technique in neurosurgery  In any surgical procedure adequate visualization of the operative field i

  13. Slide 13: How VBAS Addresses the Market's Clinical Needs: Superior Shape

    Slide 13: How VBAS Addresses the Market's Clinical Needs: Superior Shape

    OTCQB:VYCO How VBAS Addresses the Market’s Clinical Needs Superior Shape • The VBAS tubular shape disperses Discoloration of tissue retraction forces over a greater surface near the retractor tip area and has no edges where pressure build up is most common • Blunt tip allows for progressive dilation

  14. Slide 14: How VBAS Addresses the Market's Clinical Needs: Field of View

    Slide 14: How VBAS Addresses the Market's Clinical Needs: Field of View

    OTCQB:VYCO How VBAS Addresses the Market’s Clinical Needs Superior Field of View Surgical Field of View • Made of polished transparent polycarbonate Standard Retractor VBAS • Significantly increases the surgeon’s vision through clear walls • Allows for continual monitoring of surrounding tissue and

  15. Slide 15: How VBAS Addresses the Market's Clinical Needs: Working Channel

    Slide 15: How VBAS Addresses the Market's Clinical Needs: Working Channel

    OTCQB:VYCO How VBAS Addresses the Market’s Clinical Needs Improved Working Channel • Elliptical shape provides a widened working channel in one access, gives the surgeon greater working room allowing for bimanual surgical maneuvering • The contained working channel provides protection of peripheral

  16. Slide 16: How VBAS Addresses the Market's Clinical Needs: Neuronavigation

    Slide 16: How VBAS Addresses the Market's Clinical Needs: Neuronavigation

    OTCQB:VYCO How VBAS Addresses the Market’s Clinical Needs Compatible with Neuronavigation • The tip of the VBAS introducer literally becomes the “pointer” on the neuro- navigation system, allowing for real time monitoring of its position • Clip of the VBAS AC locks in place the most commonly used ne

  17. Slide 17: VBAS Saves Lives

    Slide 17: VBAS Saves Lives

    OTCQB:VYCO VBAS Saves Lives Previously Inoperable…Now Operable “Her case would have been inoperable via a traditional surgery, because she was taking Avastin®, which delays surgical wound healing. “The VBAS’ minimally invasive nature enabled the surgeon to gain access to the target through only a 3c

  18. Slide 18: Benefits Evidenced Through Extensive Clinical Data

    Slide 18: Benefits Evidenced Through Extensive Clinical Data

    OTCQB:VYCO Benefits Evidenced Through Extensive Clinical Data  Build up of clinical evidence to support the VBAS advantages has been a key management objective  VBAS has now been the subject of over 40 peer reviewed studies and numerous other clinical papers involving over 500 patients  Studies n

  19. Slide 19: ICH New Exciting Opportunity

    Slide 19: ICH New Exciting Opportunity

    OTCQB:VYCO ICH New Exciting Opportunity • Increasing Focus on ICH Evacuation Utilizing Tubular Retractors - Opening a Large New Opportunity 19

  20. Slide 20: ICH New Exciting Opportunity - continued

    Slide 20: ICH New Exciting Opportunity - continued

    OTCQB:VYCO ICH New Exciting Opportunity - continued 20

  21. Slide 21: Validated Technology

    Slide 21: Validated Technology

    OTCQB:VYCO Validated Technology Approved for Use in 350+ US Hospitals  Significant body of clinical papers and studies evidence VBAS’ clinical superiority and improved patient outcomes  International presence with regulatory approvals in key international markets  Technology protected by 46 grant

  22. Slide 22: Outsourced Business Model: Increases Efficiency

    Slide 22: Outsourced Business Model: Increases Efficiency

    OTCQB:VYCO Outsourced Business Model: Increases Efficiency  Vycor focuses on product innovation, targeted marketing, and regulatory oversight, while outsourcing operations such as manufacturing and sales  Manufacturing: outsourced to qualified sub-contract manufacturers  US sales: outsourced to 1

  23. Slide 23: Vycor Medical Product Lines: NovaVision

    Slide 23: Vycor Medical Product Lines: NovaVision

    OTCQB:VYCO Vycor Medical Product Lines NovaVision 23

  24. Slide 24: NovaVision

    Slide 24: NovaVision

    OTCQB:VYCO NovaVision NovaVision’s Suite of Complementary Therapies Addresses Patients “We do not need a new brain, but with Vision Disorders Resulting from Stroke or Brain Injury innovative methods of treatment to overcome the functional consequences of brain injury” - Prof. Josef Zihl, Ph.D., Prof

  25. Slide 25: An Important Therapy for Daily Life

    Slide 25: An Important Therapy for Daily Life

    OTCQB:VYCO An Important Therapy for Daily Life “My vision began coming back after the first month of therapy…I passed my driving test, can read normally, and enjoy driving my boat on the lake…my life is back to normal.” – Stroke survivor and VRT patient Pre-VRT Post-VRT The Impact on Daily Lives Can

  26. Slide 26: … And it Works

    Slide 26: … And it Works

    OTCQB:VYCO … And it Works Clinically Demonstrated to Restore and Make the Most of Remaining Vision “I can't put a value on what I have • VRT: 15 years of research, 20 clinical studies including a 302 gained with NeuroEyeCoach, I can just say thank you with all that I am.” patient study in which nota

  27. Slide 27: NeuroEyeCoach Highly Effective

    Slide 27: NeuroEyeCoach Highly Effective

    OTCQB:VYCO NeuroEyeCoach Highly Effective • The only dedicated visual training program specifically designed to improve scanning and eye movement: ➢ Other scanning programs in use at clinics are part of aggregated modular systems ➢ Can be completed during patient’s stay in clinic or be completed at

  28. Slide 28: NeuroEyeCoach Study

    Slide 28: NeuroEyeCoach Study

    OTCQB:VYCO NeuroEyeCoach Study Published in Cortex, this is the largest study completed to date in the neuro visual space • Analysed results of 296 patients who performed NeuroEyeCoach • Demonstrated dramatic improvement in patients’ ability to detect objects in the visual field by training them to

  29. Slide 29: NovaVision Opportunity

    Slide 29: NovaVision Opportunity

    OTCQB:VYCO NovaVision Opportunity VRT and NeuroEyeCoach are well suited capitalize on the global trend towards digital health: digitally delivered at-home treatment: • Need to discharge patients from in-patient and out-patient facility care • Health systems duty to provide care and rehabilitation •

  30. Slide 30: NovaVision: Need for Further Development

    Slide 30: NovaVision: Need for Further Development

    OTCQB:VYCO NovaVision: Need for Further Development The NovaVision therapies, while showing a positive impact on patients with visual field loss due to neurological damage, still require significant development to allow them to successfully address the multi-billion dollar market potential: • Therap

  31. Slide 31: NEC Potential in Non-HealthCare Markets

    Slide 31: NEC Potential in Non-HealthCare Markets

    OTCQB:VYCO NEC Potential in Non-HealthCare Markets NovaVision believes there is potential to move into non-healthcare markets possibly even through a JV: • Strong potential for NeuroEyeCoach technology given its strong clinical data • Potential variants for non-medical use in sports, aviation, gamin

  32. Slide 32: Contact Us

    Slide 32: Contact Us

    OTCQB:VYCO Contact Us Company Contacts Corporate Headquarters Our Websites 951 Broken Sound Parkway, www.vycormedical.com Peter Zachariou, CEO Suite 320, Boca Raton, FL 33487 www.vycorvbas.com David Cantor, President 561-558-2020 www.novavision.com info@vycormedical.com Adrian Liddell, CFO 32

Source: Internet Archive copy of vycormedical.com

More decks from Vycor Medical Inc.

All 3 Vycor Medical decks